FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer - FDA Press Releases

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.

from Food and Drug Administration--Press Releases http://ift.tt/1RbCKwj
via IFTTT